Top News

Valeant Pharmaceuticals Buys Obagi Medical For $360M

Long Beach-based Obagi Medical Products, the developer of aesthetic medicine products, is being acquired by Valeant Pharmaceuticals, in a deal worth approximately $360M, Obagi said this morning. Obagi said that Valeant has agreed to acquire all of its outstanding common stock for $19.75 per share in cash, a 42 percent premium to Obagi's closing share price on Thursday, March 14th. The firms said the deal is expected to be complete in the second quarter of 2013.


 

Marketplace


 

 

Latest Headlines

Browse Issues

 
 

Keep up with all of the latest Southern California high tech news via email (it's free!)



or Cancel